Key facts
- This is a regional norm, not an exotic diagnosis. The WHO Western Pacific Region alone has an estimated 102 million people living with chronic hepatitis B, the highest burden of any region (WHO).
- Age at infection decides almost everything. Caught in adulthood, it becomes chronic in under 5% of cases. Caught in infancy or early childhood, in about 95% (WHO).
- That single fact explains the map, and it is why the mental model most Western readers arrive with is the wrong one.
- Many people with chronic hepatitis B are monitored rather than treated, and that is an active decision, not neglect.
- Never stop a hepatitis B antiviral on your own. Most people who start treatment continue it long term, and stopping badly can cause the liver to flare.
- Hepatitis C is now a different story entirely, treated as a course rather than a lifetime.
- Everything here belongs with a specialist. This is background so the appointment makes sense, not a substitute for it.
The form is for a work permit, or a long-stay visa, or a new employer’s medical. Somebody draws blood, and two weeks later a line comes back with a result on it and no appointment attached. The clinic that took the sample is not the clinic that explains it. You go home and search in English, and the first several pages you read are written for a country where this is rare, frightening and usually somebody’s fault.
So the fortnight that follows is worse than it needs to be, and almost none of that is about the virus.
Why it is common here and rare where you are from
There is one fact that reorganises everything else, and most articles bury it.
The World Health Organization puts it plainly: hepatitis B acquired in adulthood becomes a chronic infection in less than 5% of cases, while infection in infancy and early childhood becomes chronic in about 95%. The adult immune system usually clears the virus and keeps the scar of having met it. An infant’s does not.
Now consider how the virus moves. In places where it is common, it passes most often from mother to child around birth, or between small children in the first years of life. So in a region where prevalence was already high before universal infant vaccination, each generation handed a share of infections to the next at precisely the age where the body cannot clear them.
That is the whole map. The Western Pacific Region carries an estimated 102 million chronic infections and South-East Asia another 43 million, out of roughly 240 million worldwide. It is not because of anything anyone did as an adult. It is because of when the exposure happened.
Which matters practically, because the version of hepatitis B most English-language pages describe is the adult one: sex, needles, tattoos, risk and blame. That framing is not wrong about transmission, and it is close to useless for understanding a result in a person who has carried the virus since before they can remember.
Vaccination has already changed this decisively. WHO notes that the proportion of children under five with chronic infection fell to just under 1% in 2019, down from around 5% in the pre-vaccine era. Singapore introduced universal infant vaccination in 1987 (Communicable Diseases Agency). The people testing positive today are, overwhelmingly, people born before that reached them.
Carrier, chronic, active: three words doing different jobs
People use these interchangeably, including some doctors in a hurry, and the difference is what decides whether anything happens next.
Carrier is the everyday word for someone whose body did not clear the virus and who now lives with it long term. It says nothing about whether the liver is being damaged right now.
Chronic infection is the clinical term for the same situation. Again, it describes duration and not activity.
Active disease is the one that matters for treatment. It means the virus is replicating at a level that is inflaming the liver, and that shows up in blood tests and sometimes in imaging rather than in how you feel.
The gap between the second and the third is where most of the confusion lives. You can be chronically infected for decades with a liver that looks essentially normal. You can also be chronically infected with quiet, ongoing damage and feel completely well, which is the reason the monitoring exists at all. SingHealth sets out the regional picture and the long-term risks in more detail.
Feeling fine is not evidence. It is the single most important sentence in this article. The liver does its complaining late.
Why “we will monitor you” is a plan
This is the part that lands badly. You have just been told you have a virus that can cause cirrhosis and liver cancer, and the response is a blood test in six months.
It is not indifference. Treatment for chronic hepatitis B suppresses the virus rather than eliminating it, and WHO notes that most people who start must continue long term. Starting is therefore a serious commitment, and the decision rests on whether the virus is currently doing damage, not on whether it is present. Only about 4.3% of people living with chronic hepatitis B worldwide were on antiviral treatment in 2024, and WHO’s updated guidelines estimate that more than half will eventually need it, which tells you both that under-treatment is real and that not everyone needs it today.
The monitoring is what catches the moment the answer changes. Someone in a monitoring programme who becomes eligible for treatment gets it. Someone who tested positive years ago, heard nothing useful, and never went back is the person this actually goes wrong for.
When treatment does start, WHO names tenofovir and entecavir as the oral medicines used. Lamivudine is an older option now used more selectively. You can see what we list under antivirals and by condition under chronic hepatitis B.
One warning deserves to be blunt. Do not start, stop, pause or ration a hepatitis B antiviral outside specialist care. Stopping can be followed by a flare, in which the virus rebounds and the liver inflames sharply. This is not a medicine to run down to the last tablet and see what happens, and it is the reason continuity of supply is worth planning properly rather than improvising.
If you have read our article on PrEP in Thailand you will recognise tenofovir, which appears in both settings. They are genuinely different uses with different monitoring, and one does not stand in for the other.
The other letter, and the genuinely good news
Hepatitis C sits in the same category in most people’s minds and behaves entirely differently.
| Hepatitis B | Hepatitis C | |
|---|---|---|
| Usual route in this region | Mother to child, or between young children | Blood contact, historically including unscreened transfusions and reused equipment |
| Vaccine | Yes, and highly effective | No |
| Typical treatment | Long-term suppression, often lifelong | A course of direct-acting antivirals |
| Realistic goal | Control the virus, protect the liver | Cure, in the great majority of cases |
| What “finished” looks like | Ongoing monitoring | Confirmed clearance after treatment |
That right-hand column is the most cheerful thing in this article and it is worth stating clearly, because plenty of people are still carrying an impression formed in the era of interferon and a year of misery. Modern direct-acting antivirals, sofosbuvir, daclatasvir, ledipasvir and velpatasvir among them, changed hepatitis C from a life sentence to a course of tablets for most people. Ribavirin still appears in some regimens. Browse chronic hepatitis C for what we list.
The reason this belongs in an article about hepatitis B is that people conflate the two constantly, and conclude either that B is curable, which it generally is not, or that C is hopeless, which it no longer is.
The question people ask last
Almost everybody eventually asks some version of it, usually at the end and usually awkwardly: can I give this to the people I live with?
The honest answer has two halves. Hepatitis B does transmit through blood and body fluids, so household transmission is possible, which is why testing and vaccinating close contacts is standard and worth arranging early. A vaccinated partner is a protected partner, and the vaccine protects for at least twenty years and probably for life.
The other half is what does not transmit it. Not sharing food. Not cooking for people. Not cups, cutlery, hugs, coughing or a swimming pool. This matters because the social cost of hepatitis B in parts of this region has historically been heavier than the medical cost for many people, and a good deal of that was built on the wrong half of the answer.
For a mother, there is an additional and genuinely important point: transmission around birth can be prevented, with antiviral treatment where indicated plus vaccination for the baby straight after delivery. That is a conversation to have during pregnancy rather than after.
Also worth reading
For arranging continuity of care and supply across the region, see buying medicine in Singapore and buying generic medicines in Asia. For matching a medicine name across borders, see the medicine brand-name decoder.
FAQ
Does a positive result mean I will get liver cancer?
No. It means you belong in a monitoring programme, which is precisely the mechanism that prevents most of the bad outcomes. The risk is real and it is managed, and the people who do badly are usually the ones nobody followed up.
I was vaccinated as a child. Can I still test positive?
The vaccine is highly effective, though no vaccine is universal, and some people test positive for antibodies from past exposure rather than for active infection. Which marker came back positive changes the meaning entirely, and this is exactly the sort of thing worth having explained rather than interpreted from a search.
Can I work, travel and get a visa with chronic hepatitis B?
Rules vary by country and by role, and a general article is the wrong place to promise anything. What is worth knowing is that requirements differ widely between employers and jurisdictions, and that a documented, monitored, stable condition is a much stronger position than an unexplained result.
Why is my liver test normal if I have a virus in my liver?
Because chronic hepatitis B is often quiet for long stretches. Normal results today are good news about today, and the reason the test is repeated is that the situation can change without any symptom to announce it.
Should I take milk thistle or a liver supplement?
There is no good evidence that supplements change the course of chronic hepatitis B, and some herbal products are themselves hard on the liver. Tell whoever monitors you about anything you take, including things bought without a conversation.
Sources
- World Health Organization, hepatitis B fact sheet
- WHO Western Pacific, regional hepatitis data
- SingHealth, hepatitis B
- HealthHub Singapore, hepatitis B
- Singapore Communicable Diseases Agency, hepatitis B
This article is general information, checked on 10 August 2026. It contains no doses and no treatment schedules, and it is not a substitute for specialist care.
